European Medicines Agency starts rolling review of bamlanivimab and etesemivab for COVID-19

EMA’s human medicines committee (CHMP) has started a ‘rolling review’ of data on the antibodies bamlanivimab and etesemivab. The review will also look at bamlanivimab used alone. EMA has started evaluating the first batch of data, which come from animal studies.

Source:

European Medicines Agency